logo
Share SHARE
FONT-SIZE Plus   Neg

Reports: Deutsche Bank To Pay $32.5 Mln To Settle Mortgage Suit

German lender Deutsche Bank AG (DB) has agreed to pay $32.5 million to investors to settle a mortgage lawsuit, according to media reports on Monday.

The investors that sued, including lead plaintiff Massachusetts Bricklayers and Masons Trust Funds, have reportedly filed a motion on Monday for preliminary approval of the settlement in federal court in Central Islip, New York.

"The proposed settlement will provide a substantial monetary benefit to the settlement class," lawyers for the plaintiffs reportedly wrote in the filing. The deal must be approved by U.S. District Judge Leonard Wexler.

The investors had alleged they were misled about the quality of mortgage loans sold to them in 2006 as highly rated securities. They filed a lawsuit against Deutsche Bank in 2008.

The settlement is among a handful with major banks to resolve claims that they misled investors into buying risky mortgage-backed securities amid the housing boom.

In December, Bank of America Corp.'s (BAC) Merrill Lynch unit said it would pay $315 million to resolve a lawsuit brought by investors in 18 mortgage-backed securities trusts.

Wells Fargo & Co. (WFC) agreed to pay $125 million to investors to settle litigation against the company, two weeks before a scheduled hearing in July.

In early February, the U.S. federal government and attorneys general from forty-nine states reached a landmark $25 billion settlement with the nation's five largest mortgage servicers to address mortgage loan servicing and foreclosure abuses, the U.S. Department of Justice said.

The mortgage servicers who reached the settlement are Bank of America Corp. (BAC), JPMorgan Chase & Co. (JPM), Wells Fargo & Co., Citigroup Inc. (C), and Ally Financial Inc. (ALLY).

DB closed Monday's trading at $52.16, up $1.23 or 2.42 percent on a volume of 1.08 million shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Rare commodities are worth more than good is a Chinese adage. And more so when it is in the sought-after drug space. Rare and ultra-rare diseases, also called orphan and ultra-orphan diseases, as the names imply, affect very small numbers of patients. So why the clamor? Shares of steel giant ArcelorMittal were losing around 4 percent in the early morning trading in Amsterdam after the company reported sharp decline in first-quarter EBITDA, a key earnings metric, as sales were weak with lower prices and production. Net loss, however, narrowed from last year. The company also confirmed its forecast for annual EBITDA, which is lower than last year. As the din settles down on a dismal quarter at one of the world's exciting tech company, it is time to sit back and take stock of what went wrong and will the wrong be righted in the near term?
comments powered by Disqus
Follow RTT